<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04223232</url>
  </required_header>
  <id_info>
    <org_study_id>MD1003CT2019-03MB</org_study_id>
    <nct_id>NCT04223232</nct_id>
  </id_info>
  <brief_title>Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-MD1003 in Healthy Male Subjects</brief_title>
  <official_title>An Open-Label, Single-Dose, Single-Period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-MD1003 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedDay Pharmaceuticals SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quotient Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>MedDay Pharmaceuticals SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This single-center, open-label, non randomized Phase I study is being conducted to&#xD;
      investigate the pharmacokinetics, mass balance and metabolite profiling and identification&#xD;
      after a single oral dose of 100mg of [14C]-MD1003 in 6 healthy males subjects. The&#xD;
      radioactivity will be followed in the blood, urine and faeces to study MD1003 metabolism.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 10, 2019</start_date>
  <completion_date type="Actual">January 22, 2020</completion_date>
  <primary_completion_date type="Actual">January 22, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mass Balance Recovery of Total Radioactivity: CumAe (Urine)</measure>
    <time_frame>Pre-dose to 312 hours post-dose</time_frame>
    <description>Cumulative amount of total radioactivity excreted in urine Measured at 0/12/24/48/72/96/120/144/168/192/216/240/264/288/312 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mass Balance Recovery of Total Radioactivity: Cum%Ae (Urine)</measure>
    <time_frame>Pre-dose to 312 hours post dose</time_frame>
    <description>Cumulative amount of total radioactivity excreted in urine expressed as a percentage of the radioactive dose administered Measured at 0/0.5/1/1.5/2/3/4/6/8/12/18/24/36/48/72/96/120/144/168/192/216/240/264/288/312 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mass Balance Recovery of Total Radioactivity: CumAe (Faeces)</measure>
    <time_frame>Pre-dose to 312 hours post-dose</time_frame>
    <description>Cumulative amount of total radioactivity excreted in faeces Measured at 0/0.5/1/1.5/2/3/4/6/8/12/18/24/36/48/72/96/120/144/168/192/216/240/264/288/312 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mass Balance Recovery of Total Radioactivity: Cum%Ae (Faeces)</measure>
    <time_frame>Pre-dose to 312 hours post dose</time_frame>
    <description>Cumulative amount of total radioactivity excreted in faeces expressed as a percentage of the radioactive dose administered Measured at 0/0.5/1/1.5/2/3/4/6/8/12/18/24/36/48/72/96/120/144/168/192/216/240/264/288/312 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mass Balance Recovery of Total Radioactivity: CumAe(Total)</measure>
    <time_frame>Pre-dose to 312 hours post dose</time_frame>
    <description>Cumulative amount of total radioactivity excreted in urine and faeces combined Measured at 0/0.5/1/1.5/2/3/4/6/8/12/18/24/36/48/72/96/120/144/168/192/216/240/264/288/312 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mass Balance Recovery of Total Radioactivity: Cum%Ae (Total)</measure>
    <time_frame>Pre-dose to 312 hours post dose</time_frame>
    <description>Cumulative amount of total radioactivity excreted in urine and faeces combined expressed as a percentage of the radioactive dose administered Measured at 0/0.5/1/1.5/2/3/4/6/8/12/18/24/36/48/72/96/120/144/168/192/216/240/264/288/312 hours.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time Prior to the First Measurable Concentration (Tlag) for MD1003, Bisnorbiotin, Biotin Sulfoxide and Total Radioactivity</measure>
    <time_frame>Pre-dose to 168 hours</time_frame>
    <description>Measured at 0/1/1.5/2/3/4/6/8/12/18/24/36/48/72/96/120/144/168 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Maximum Plasma Concentration (Tmax) for MD1003, Bisnorbiotin, Biotin Sulfoxide and Total Radioactivity</measure>
    <time_frame>Pre-dose to 168 hours</time_frame>
    <description>Measured at 0/1/1.5/2/3/4/6/8/12/18/24/36/48/72/96/120/144/168 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) for MD1003, Bisnorbiotin, Biotin Sulfoxide and Total Radioactivity</measure>
    <time_frame>Pre-dose to 168 hours</time_frame>
    <description>Measured at 0/1/1.5/2/3/4/6/8/12/18/24/36/48/72/96/120/144/168 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Plasma Concentration Curve From 0 Time to Last Measurable Concentration (AUC(0-last)) for MD1003, Bisnorbiotin, Biotin Sulfoxide and Total Radioactivity</measure>
    <time_frame>Pre-dose to 168 hours</time_frame>
    <description>Measured at 0/1/1.5/2/3/4/6/8/12/18/24/36/48/72/96/120/144/168 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Plasma Concentration Curve From 0 Time Extrapolated to Infinity (AUC(0-inf)) for MD1003 and Total Radioactivity</measure>
    <time_frame>Pre-dose to 168 hours</time_frame>
    <description>Measured at 0/1/1.5/2/3/4/6/8/12/18/24/36/48/72/96/120/144/168 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of AUC(0-extrap) Extrapolated Beyond the Last Measurable Concentration for MD1003 and Total Radioactivity</measure>
    <time_frame>Pre-dose to 168 hours</time_frame>
    <description>Measured at 0/1/1.5/2/3/4/6/8/12/18/24/36/48/72/96/120/144/168 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Plasma Concentration Curve From 0 Time to Last Measurable Concentration (AUC(0-12)) for MD1003, Bisnorbiotin, Biotin Sulfoxide and Total Radioactivity</measure>
    <time_frame>Pre-dose to 168 hours</time_frame>
    <description>Measured at 0/1/1.5/2/3/4/6/8/12/18/24/36/48/72/96/120/144/168 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lambda-z for MD1003, Bisnorbiotin, Biotin Sulfoxide and Total Radioactivity</measure>
    <time_frame>Pre-dose to 168 hours</time_frame>
    <description>Measured at 0/1/1.5/2/3/4/6/8/12/18/24/36/48/72/96/120/144/168 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Clearance (CL/F) for MD1003</measure>
    <time_frame>Pre-dose to 168 hours</time_frame>
    <description>Measured at 0/1/1.5/2/3/4/6/8/12/18/24/36/48/72/96/120/144/168 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Clearance (Vz/F) for MD1003</measure>
    <time_frame>Pre-dose to 168 hours</time_frame>
    <description>Measured at 0/1/1.5/2/3/4/6/8/12/18/24/36/48/72/96/120/144/168 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination Half Life (t1/2) for MD1003, Bisnorbiotin, Biotin Sulfoxide and Total Radioactivity</measure>
    <time_frame>Pre-dose to 168 hours</time_frame>
    <description>Measured at 0//1/1.5/2/3/4/6/8/12/18/24/36/48/72/96/120/144/168 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MPR Cmax for Bisnorbiotin and Biotin Sulfoxide</measure>
    <time_frame>Pre-dose to 168 hours</time_frame>
    <description>MPR = metabolite to parent ratio Measured at 0/1/1.5/2/3/4/6/8/12/18/24/36/48/72/96/120/144/168 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MPR AUC(0-inf) for Bisnorbiotin and Biotin Sulfoxide</measure>
    <time_frame>Pre-dose to 168 hours</time_frame>
    <description>MPR = metabolite to parent ratio Measured at 0/1/1.5/2/3/4/6/8/12/18/24/36/48/72/96/120/144/168 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whole Blood: Plasma Concentration Ratios of Total Radioactivity</measure>
    <time_frame>Pre-dose to 168 hours post-dose</time_frame>
    <description>Total radioactivity in whole blood versus total radioactivity in plasma concentration ratios at time intervals following a single oral administration of 100mg [14C]-MD1003 Measured at 0/1/1.5/2/3/4/6/8/12/18/24/36/48/72/96/120/144/168 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Adverse Events (AEs)</measure>
    <time_frame>Overall period</time_frame>
    <description>2 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Adverse Drug Reactions as Assessed by Investigator</measure>
    <time_frame>Overall period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Systolic Blood Pressure in mmHg</measure>
    <time_frame>Pre-dose to Day 10</time_frame>
    <description>Change from baseline measure (defined as Day 1, pre-dose). Measured at screening/Pre-dose/1/4/24/72/168 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Diastolic Blood Pressure in mmHg</measure>
    <time_frame>Pre-dose to Day 10</time_frame>
    <description>Change from baseline measure (defined as Day 1, pre-dose). Measured at screening/Pre-dose/1/4/24/72/168 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Heart Rate in Beats Per Minute</measure>
    <time_frame>Pre-dose to Day 10</time_frame>
    <description>Change from baseline measure (defined as Day 1, pre-dose). Measured at screening/Pre-dose/1/4/24/72/168 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in ECG (Electrocardiogram) QTcF Interval in Milliseconds</measure>
    <time_frame>Pre-dose to Day 10</time_frame>
    <description>Change from baseline measure (defined as Day 1, pre-dose). Measured at screening/Pre-dose/1/4/24/72/168 hours.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>MD1003</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>radiolabeled 14C MD1003 (High Dose Biotin) 100mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]-MD1003</intervention_name>
    <description>single oral dose of 100mg [14C]-MD1003</description>
    <arm_group_label>MD1003</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy males&#xD;
&#xD;
          2. Age 30 to 65 years of age at the time of signing informed consent&#xD;
&#xD;
          3. Body mass index (BMI) of 18.0 to 30.0 kg/m2 as measured at screening&#xD;
&#xD;
          4. Must be willing and able to communicate and participate in the whole study&#xD;
&#xD;
          5. Must have regular bowel movements (ie average stool production of ≥1 and ≤3 stools per&#xD;
             day)&#xD;
&#xD;
          6. Must provide written informed consent&#xD;
&#xD;
          7. Must agree to adhere to the contraception requirements of the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who have received any IMP in a clinical research study within the 90 days&#xD;
             prior to Day 1&#xD;
&#xD;
          2. Subjects who are study site employees, or immediate family members of a study site or&#xD;
             sponsor employee&#xD;
&#xD;
          3. Subjects who have previously been enrolled in this study&#xD;
&#xD;
          4. History of any drug or alcohol abuse in the past 2 years&#xD;
&#xD;
          5. Regular alcohol consumption in males &gt;21 units per week (1 unit = ½ pint beer, or a 25&#xD;
             mL shot of 40% spirit, 1.5 to 2 Units = 125 mL glass of wine, depending on type)&#xD;
&#xD;
          6. A confirmed positive alcohol breath test at screening or admission&#xD;
&#xD;
          7. Current smokers and those who have smoked within the last 12 months. A confirmed&#xD;
             breath carbon monoxide reading of greater than 10 ppm at screening or admission&#xD;
&#xD;
          8. Current users of e-cigarettes and nicotine replacement products and those who have&#xD;
             used these products within the last 12 months&#xD;
&#xD;
          9. Subjects with pregnant or lactating partners&#xD;
&#xD;
         10. Radiation exposure, including that from the present study, excluding background&#xD;
             radiation but including diagnostic X-rays and other medical exposures, exceeding 5 mSv&#xD;
             in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker,&#xD;
             as defined in the Ionising Radiation Regulations 2017, shall participate in the study&#xD;
&#xD;
         11. Subjects who do not have suitable veins for multiple venepunctures/cannulation as&#xD;
             assessed by the investigator or delegate at screening&#xD;
&#xD;
         12. Clinically significant abnormal clinical chemistry, haematology or urinalysis as&#xD;
             judged by the investigator. Subjects with Gilbert's Syndrome are allowed&#xD;
&#xD;
         13. Confirmed positive drugs of abuse test result (drugs of abuse tests are listed in the&#xD;
             protocol)&#xD;
&#xD;
         14. Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or&#xD;
             human immunodeficiency virus (HIV) results&#xD;
&#xD;
         15. Evidence of renal impairment at screening, as indicated by an estimated creatinine&#xD;
             clearance of &lt;80 mL/min using the Cockcroft-Gault equation&#xD;
&#xD;
         16. History of clinically significant cardiovascular, renal, hepatic, chronic respiratory&#xD;
             or gastrointestinal disease, neurological or psychiatric disorder, as judged by the&#xD;
             investigator&#xD;
&#xD;
         17. Serious adverse reaction or serious hypersensitivity to any drug or the formulation&#xD;
             excipients&#xD;
&#xD;
         18. Presence or history of clinically significant allergy requiring treatment, as judged&#xD;
             by the investigator. Hay fever is allowed unless it is active&#xD;
&#xD;
         19. Donation or loss of greater than 400 mL of blood within the previous 3 months&#xD;
&#xD;
         20. Subjects who are taking, or have taken, any prescribed or over-the-counter drug (other&#xD;
             than 4 g of paracetamol per day), herbal remedies, vitamin B5 or dietary supplements&#xD;
             containing lipoic acid in the 14 days before IMP administration. Exceptions may apply&#xD;
             on a case by case basis, if considered not to interfere with the objectives of the&#xD;
             study, as determined by the PI&#xD;
&#xD;
         21. Subjects who have had any intake of biotin (including as a nutritional supplement) in&#xD;
             the 14 days before IMP administration&#xD;
&#xD;
         22. Failure to satisfy the investigator of fitness to participate for any other reason&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Somasekhara Menakuru, MS, MRCS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quotient Sciences Nottingham, UK, NG116JS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quotient Sciences</name>
      <address>
        <city>Nottingham</city>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>December 13, 2019</study_first_submitted>
  <study_first_submitted_qc>January 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 10, 2020</study_first_posted>
  <results_first_submitted>September 21, 2020</results_first_submitted>
  <results_first_submitted_qc>October 29, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 2, 2020</results_first_posted>
  <last_update_submitted>October 29, 2020</last_update_submitted>
  <last_update_submitted_qc>October 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 12, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/32/NCT04223232/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 2, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/32/NCT04223232/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>MD1003</title>
          <description>radiolabeled 14C MD1003 (High Dose Biotin) 100mg&#xD;
[14C]-MD1003: single oral dose of 100mg [14C]-MD1003</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MD1003</title>
          <description>radiolabeled 14C MD1003 (High Dose Biotin) 100mg&#xD;
[14C]-MD1003: single oral dose of 100mg [14C]-MD1003</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.3" spread="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mass Balance Recovery of Total Radioactivity: CumAe (Urine)</title>
        <description>Cumulative amount of total radioactivity excreted in urine Measured at 0/12/24/48/72/96/120/144/168/192/216/240/264/288/312 hours</description>
        <time_frame>Pre-dose to 312 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MD1003</title>
            <description>radiolabeled 14C MD1003 (High Dose Biotin) 100mg&#xD;
[14C]-MD1003: single oral dose of 100mg [14C]-MD1003</description>
          </group>
        </group_list>
        <measure>
          <title>Mass Balance Recovery of Total Radioactivity: CumAe (Urine)</title>
          <description>Cumulative amount of total radioactivity excreted in urine Measured at 0/12/24/48/72/96/120/144/168/192/216/240/264/288/312 hours</description>
          <units>mg equiv</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.9" spread="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mass Balance Recovery of Total Radioactivity: Cum%Ae (Urine)</title>
        <description>Cumulative amount of total radioactivity excreted in urine expressed as a percentage of the radioactive dose administered Measured at 0/0.5/1/1.5/2/3/4/6/8/12/18/24/36/48/72/96/120/144/168/192/216/240/264/288/312 hours.</description>
        <time_frame>Pre-dose to 312 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MD1003</title>
            <description>radiolabeled 14C MD1003 (High Dose Biotin) 100mg&#xD;
[14C]-MD1003: single oral dose of 100mg [14C]-MD1003</description>
          </group>
        </group_list>
        <measure>
          <title>Mass Balance Recovery of Total Radioactivity: Cum%Ae (Urine)</title>
          <description>Cumulative amount of total radioactivity excreted in urine expressed as a percentage of the radioactive dose administered Measured at 0/0.5/1/1.5/2/3/4/6/8/12/18/24/36/48/72/96/120/144/168/192/216/240/264/288/312 hours.</description>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.786" spread="16.874"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mass Balance Recovery of Total Radioactivity: CumAe (Faeces)</title>
        <description>Cumulative amount of total radioactivity excreted in faeces Measured at 0/0.5/1/1.5/2/3/4/6/8/12/18/24/36/48/72/96/120/144/168/192/216/240/264/288/312 hours.</description>
        <time_frame>Pre-dose to 312 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MD1003</title>
            <description>radiolabeled 14C MD1003 (High Dose Biotin) 100mg&#xD;
[14C]-MD1003: single oral dose of 100mg [14C]-MD1003</description>
          </group>
        </group_list>
        <measure>
          <title>Mass Balance Recovery of Total Radioactivity: CumAe (Faeces)</title>
          <description>Cumulative amount of total radioactivity excreted in faeces Measured at 0/0.5/1/1.5/2/3/4/6/8/12/18/24/36/48/72/96/120/144/168/192/216/240/264/288/312 hours.</description>
          <units>mg equiv</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0" spread="8.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mass Balance Recovery of Total Radioactivity: Cum%Ae (Faeces)</title>
        <description>Cumulative amount of total radioactivity excreted in faeces expressed as a percentage of the radioactive dose administered Measured at 0/0.5/1/1.5/2/3/4/6/8/12/18/24/36/48/72/96/120/144/168/192/216/240/264/288/312 hours.</description>
        <time_frame>Pre-dose to 312 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MD1003</title>
            <description>radiolabeled 14C MD1003 (High Dose Biotin) 100mg&#xD;
[14C]-MD1003: single oral dose of 100mg [14C]-MD1003</description>
          </group>
        </group_list>
        <measure>
          <title>Mass Balance Recovery of Total Radioactivity: Cum%Ae (Faeces)</title>
          <description>Cumulative amount of total radioactivity excreted in faeces expressed as a percentage of the radioactive dose administered Measured at 0/0.5/1/1.5/2/3/4/6/8/12/18/24/36/48/72/96/120/144/168/192/216/240/264/288/312 hours.</description>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.009" spread="8.617"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mass Balance Recovery of Total Radioactivity: CumAe(Total)</title>
        <description>Cumulative amount of total radioactivity excreted in urine and faeces combined Measured at 0/0.5/1/1.5/2/3/4/6/8/12/18/24/36/48/72/96/120/144/168/192/216/240/264/288/312 hours.</description>
        <time_frame>Pre-dose to 312 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MD1003</title>
            <description>radiolabeled 14C MD1003 (High Dose Biotin) 100mg&#xD;
[14C]-MD1003: single oral dose of 100mg [14C]-MD1003</description>
          </group>
        </group_list>
        <measure>
          <title>Mass Balance Recovery of Total Radioactivity: CumAe(Total)</title>
          <description>Cumulative amount of total radioactivity excreted in urine and faeces combined Measured at 0/0.5/1/1.5/2/3/4/6/8/12/18/24/36/48/72/96/120/144/168/192/216/240/264/288/312 hours.</description>
          <units>mg equiv</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.9" spread="9.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mass Balance Recovery of Total Radioactivity: Cum%Ae (Total)</title>
        <description>Cumulative amount of total radioactivity excreted in urine and faeces combined expressed as a percentage of the radioactive dose administered Measured at 0/0.5/1/1.5/2/3/4/6/8/12/18/24/36/48/72/96/120/144/168/192/216/240/264/288/312 hours.</description>
        <time_frame>Pre-dose to 312 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MD1003</title>
            <description>radiolabeled 14C MD1003 (High Dose Biotin) 100mg&#xD;
[14C]-MD1003: single oral dose of 100mg [14C]-MD1003</description>
          </group>
        </group_list>
        <measure>
          <title>Mass Balance Recovery of Total Radioactivity: Cum%Ae (Total)</title>
          <description>Cumulative amount of total radioactivity excreted in urine and faeces combined expressed as a percentage of the radioactive dose administered Measured at 0/0.5/1/1.5/2/3/4/6/8/12/18/24/36/48/72/96/120/144/168/192/216/240/264/288/312 hours.</description>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.795" spread="9.235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Prior to the First Measurable Concentration (Tlag) for MD1003, Bisnorbiotin, Biotin Sulfoxide and Total Radioactivity</title>
        <description>Measured at 0/1/1.5/2/3/4/6/8/12/18/24/36/48/72/96/120/144/168 hours.</description>
        <time_frame>Pre-dose to 168 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MD1003</title>
            <description>radiolabeled 14C MD1003 (High Dose Biotin) 100mg&#xD;
[14C]-MD1003: single oral dose of 100mg [14C]-MD1003</description>
          </group>
        </group_list>
        <measure>
          <title>Time Prior to the First Measurable Concentration (Tlag) for MD1003, Bisnorbiotin, Biotin Sulfoxide and Total Radioactivity</title>
          <description>Measured at 0/1/1.5/2/3/4/6/8/12/18/24/36/48/72/96/120/144/168 hours.</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MD1003</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.083" lower_limit="0.00" upper_limit="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bisnorbiotin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.753" lower_limit="0.50" upper_limit="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Biotin Sulfoxide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.753" lower_limit="0.50" upper_limit="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total radioactivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time of Maximum Plasma Concentration (Tmax) for MD1003, Bisnorbiotin, Biotin Sulfoxide and Total Radioactivity</title>
        <description>Measured at 0/1/1.5/2/3/4/6/8/12/18/24/36/48/72/96/120/144/168 hours.</description>
        <time_frame>Pre-dose to 168 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MD1003</title>
            <description>radiolabeled 14C MD1003 (High Dose Biotin) 100mg&#xD;
[14C]-MD1003: single oral dose of 100mg [14C]-MD1003</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Maximum Plasma Concentration (Tmax) for MD1003, Bisnorbiotin, Biotin Sulfoxide and Total Radioactivity</title>
          <description>Measured at 0/1/1.5/2/3/4/6/8/12/18/24/36/48/72/96/120/144/168 hours.</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MD1003</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.086" lower_limit="1.52" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bisnorbiotin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.011" lower_limit="3.00" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Biotin Sulfoxide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.667" lower_limit="2.00" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total radioactivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.667" lower_limit="2.00" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Concentration (Cmax) for MD1003, Bisnorbiotin, Biotin Sulfoxide and Total Radioactivity</title>
        <description>Measured at 0/1/1.5/2/3/4/6/8/12/18/24/36/48/72/96/120/144/168 hours.</description>
        <time_frame>Pre-dose to 168 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MD1003</title>
            <description>radiolabeled 14C MD1003 (High Dose Biotin) 100mg&#xD;
[14C]-MD1003: single oral dose of 100mg [14C]-MD1003</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) for MD1003, Bisnorbiotin, Biotin Sulfoxide and Total Radioactivity</title>
          <description>Measured at 0/1/1.5/2/3/4/6/8/12/18/24/36/48/72/96/120/144/168 hours.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MD1003</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="387" lower_limit="325" upper_limit="416"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bisnorbiotin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.5" lower_limit="26.4" upper_limit="59.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Biotin Sulfoxide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5" lower_limit="9.70" upper_limit="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total radioactivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="501" lower_limit="469" upper_limit="543"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under Plasma Concentration Curve From 0 Time to Last Measurable Concentration (AUC(0-last)) for MD1003, Bisnorbiotin, Biotin Sulfoxide and Total Radioactivity</title>
        <description>Measured at 0/1/1.5/2/3/4/6/8/12/18/24/36/48/72/96/120/144/168 hours.</description>
        <time_frame>Pre-dose to 168 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MD1003</title>
            <description>radiolabeled 14C MD1003 (High Dose Biotin) 100mg&#xD;
[14C]-MD1003: single oral dose of 100mg [14C]-MD1003</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under Plasma Concentration Curve From 0 Time to Last Measurable Concentration (AUC(0-last)) for MD1003, Bisnorbiotin, Biotin Sulfoxide and Total Radioactivity</title>
          <description>Measured at 0/1/1.5/2/3/4/6/8/12/18/24/36/48/72/96/120/144/168 hours.</description>
          <units>ng.h/mL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MD1003</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3350" lower_limit="2750" upper_limit="4480"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bisnorbiotin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="514" lower_limit="246" upper_limit="890"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Biotin Sulfoxide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.3" lower_limit="47.4" upper_limit="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total radioactivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2690" lower_limit="2490" upper_limit="3310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under Plasma Concentration Curve From 0 Time Extrapolated to Infinity (AUC(0-inf)) for MD1003 and Total Radioactivity</title>
        <description>Measured at 0/1/1.5/2/3/4/6/8/12/18/24/36/48/72/96/120/144/168 hours.</description>
        <time_frame>Pre-dose to 168 hours</time_frame>
        <population>For total radioactivity: for 3 patients, extrapolated portion of AUC(0-inf) &gt;20%.</population>
        <group_list>
          <group group_id="O1">
            <title>MD1003</title>
            <description>radiolabeled 14C MD1003 (High Dose Biotin) 100mg&#xD;
[14C]-MD1003: single oral dose of 100mg [14C]-MD1003</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under Plasma Concentration Curve From 0 Time Extrapolated to Infinity (AUC(0-inf)) for MD1003 and Total Radioactivity</title>
          <description>Measured at 0/1/1.5/2/3/4/6/8/12/18/24/36/48/72/96/120/144/168 hours.</description>
          <population>For total radioactivity: for 3 patients, extrapolated portion of AUC(0-inf) &gt;20%.</population>
          <units>ng.h/mL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MD1003</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3650" lower_limit="3010" upper_limit="4750"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total radioactivity</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2850" lower_limit="2670" upper_limit="3060"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of AUC(0-extrap) Extrapolated Beyond the Last Measurable Concentration for MD1003 and Total Radioactivity</title>
        <description>Measured at 0/1/1.5/2/3/4/6/8/12/18/24/36/48/72/96/120/144/168 hours.</description>
        <time_frame>Pre-dose to 168 hours</time_frame>
        <population>For total radioactivity: for 3 patients, extrapolated portion of AUC(0-inf) &gt;20%.</population>
        <group_list>
          <group group_id="O1">
            <title>MD1003</title>
            <description>radiolabeled 14C MD1003 (High Dose Biotin) 100mg&#xD;
[14C]-MD1003: single oral dose of 100mg [14C]-MD1003</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of AUC(0-extrap) Extrapolated Beyond the Last Measurable Concentration for MD1003 and Total Radioactivity</title>
          <description>Measured at 0/1/1.5/2/3/4/6/8/12/18/24/36/48/72/96/120/144/168 hours.</description>
          <population>For total radioactivity: for 3 patients, extrapolated portion of AUC(0-inf) &gt;20%.</population>
          <units>percentage of AUC(0-extrap)</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MD1003</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.405" lower_limit="5.76" upper_limit="11.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total radioactivity</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.171" lower_limit="10.15" upper_limit="18.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under Plasma Concentration Curve From 0 Time to Last Measurable Concentration (AUC(0-12)) for MD1003, Bisnorbiotin, Biotin Sulfoxide and Total Radioactivity</title>
        <description>Measured at 0/1/1.5/2/3/4/6/8/12/18/24/36/48/72/96/120/144/168 hours.</description>
        <time_frame>Pre-dose to 168 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MD1003</title>
            <description>radiolabeled 14C MD1003 (High Dose Biotin) 100mg&#xD;
[14C]-MD1003: single oral dose of 100mg [14C]-MD1003</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under Plasma Concentration Curve From 0 Time to Last Measurable Concentration (AUC(0-12)) for MD1003, Bisnorbiotin, Biotin Sulfoxide and Total Radioactivity</title>
          <description>Measured at 0/1/1.5/2/3/4/6/8/12/18/24/36/48/72/96/120/144/168 hours.</description>
          <units>ng.h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MD1003</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1760" spread="16.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bisnorbiotin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="279" spread="26.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Biotin Sulfoxide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.1" spread="23.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total radioactivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2680" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lambda-z for MD1003, Bisnorbiotin, Biotin Sulfoxide and Total Radioactivity</title>
        <description>Measured at 0/1/1.5/2/3/4/6/8/12/18/24/36/48/72/96/120/144/168 hours.</description>
        <time_frame>Pre-dose to 168 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MD1003</title>
            <description>radiolabeled 14C MD1003 (High Dose Biotin) 100mg&#xD;
[14C]-MD1003: single oral dose of 100mg [14C]-MD1003</description>
          </group>
        </group_list>
        <measure>
          <title>Lambda-z for MD1003, Bisnorbiotin, Biotin Sulfoxide and Total Radioactivity</title>
          <description>Measured at 0/1/1.5/2/3/4/6/8/12/18/24/36/48/72/96/120/144/168 hours.</description>
          <units>1/Hours</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MD1003</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02302" lower_limit="0.0180" upper_limit="0.0269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bisnorbiotin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02251" lower_limit="0.0165" upper_limit="0.0285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Biotin Sulfoxide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11829" lower_limit="0.0324" upper_limit="0.1683"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total radioactivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20071" lower_limit="0.0756" upper_limit="0.3762"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Clearance (CL/F) for MD1003</title>
        <description>Measured at 0/1/1.5/2/3/4/6/8/12/18/24/36/48/72/96/120/144/168 hours.</description>
        <time_frame>Pre-dose to 168 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MD1003</title>
            <description>radiolabeled 14C MD1003 (High Dose Biotin) 100mg&#xD;
[14C]-MD1003: single oral dose of 100mg [14C]-MD1003</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Clearance (CL/F) for MD1003</title>
          <description>Measured at 0/1/1.5/2/3/4/6/8/12/18/24/36/48/72/96/120/144/168 hours.</description>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="465" lower_limit="351" upper_limit="554"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Clearance (Vz/F) for MD1003</title>
        <description>Measured at 0/1/1.5/2/3/4/6/8/12/18/24/36/48/72/96/120/144/168 hours.</description>
        <time_frame>Pre-dose to 168 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MD1003</title>
            <description>radiolabeled 14C MD1003 (High Dose Biotin) 100mg&#xD;
[14C]-MD1003: single oral dose of 100mg [14C]-MD1003</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Clearance (Vz/F) for MD1003</title>
          <description>Measured at 0/1/1.5/2/3/4/6/8/12/18/24/36/48/72/96/120/144/168 hours.</description>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1230" lower_limit="816" upper_limit="1560"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Elimination Half Life (t1/2) for MD1003, Bisnorbiotin, Biotin Sulfoxide and Total Radioactivity</title>
        <description>Measured at 0//1/1.5/2/3/4/6/8/12/18/24/36/48/72/96/120/144/168 hours.</description>
        <time_frame>Pre-dose to 168 hours</time_frame>
        <population>For Bisnorbiotin: terminal slopes could not be reliably determined for all, due to an unacceptable coefficient of determination (ie, R2 &lt; 0.9).&#xD;
For Biotin sulfoxide: terminal slopes could not be reliably determined all, due to an unacceptable coefficient of determination (ie, R2 &lt; 0.9) or insufficient data points after Cmax.</population>
        <group_list>
          <group group_id="O1">
            <title>MD1003</title>
            <description>radiolabeled 14C MD1003 (High Dose Biotin) 100mg&#xD;
[14C]-MD1003: single oral dose of 100mg [14C]-MD1003</description>
          </group>
        </group_list>
        <measure>
          <title>Elimination Half Life (t1/2) for MD1003, Bisnorbiotin, Biotin Sulfoxide and Total Radioactivity</title>
          <description>Measured at 0//1/1.5/2/3/4/6/8/12/18/24/36/48/72/96/120/144/168 hours.</description>
          <population>For Bisnorbiotin: terminal slopes could not be reliably determined for all, due to an unacceptable coefficient of determination (ie, R2 &lt; 0.9).&#xD;
For Biotin sulfoxide: terminal slopes could not be reliably determined all, due to an unacceptable coefficient of determination (ie, R2 &lt; 0.9) or insufficient data points after Cmax.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MD1003</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.625" lower_limit="25.74" upper_limit="38.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bisnorbiotin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.176" lower_limit="24.29" upper_limit="42.065"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Biotin Sulfoxide</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.010" lower_limit="4.12" upper_limit="21.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total radioactivity</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.502" lower_limit="1.84" upper_limit="9.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MPR Cmax for Bisnorbiotin and Biotin Sulfoxide</title>
        <description>MPR = metabolite to parent ratio Measured at 0/1/1.5/2/3/4/6/8/12/18/24/36/48/72/96/120/144/168 hours.</description>
        <time_frame>Pre-dose to 168 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MD1003</title>
            <description>radiolabeled 14C MD1003 (High Dose Biotin) 100mg&#xD;
[14C]-MD1003: single oral dose of 100mg [14C]-MD1003</description>
          </group>
        </group_list>
        <measure>
          <title>MPR Cmax for Bisnorbiotin and Biotin Sulfoxide</title>
          <description>MPR = metabolite to parent ratio Measured at 0/1/1.5/2/3/4/6/8/12/18/24/36/48/72/96/120/144/168 hours.</description>
          <units>none (ratio)</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bisnorbiotin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1327" lower_limit="0.074" upper_limit="0.174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Biotin Sulfoxide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0349" lower_limit="0.028" upper_limit="0.044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MPR AUC(0-inf) for Bisnorbiotin and Biotin Sulfoxide</title>
        <description>MPR = metabolite to parent ratio Measured at 0/1/1.5/2/3/4/6/8/12/18/24/36/48/72/96/120/144/168 hours.</description>
        <time_frame>Pre-dose to 168 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MD1003</title>
            <description>radiolabeled 14C MD1003 (High Dose Biotin) 100mg&#xD;
[14C]-MD1003: single oral dose of 100mg [14C]-MD1003</description>
          </group>
        </group_list>
        <measure>
          <title>MPR AUC(0-inf) for Bisnorbiotin and Biotin Sulfoxide</title>
          <description>MPR = metabolite to parent ratio Measured at 0/1/1.5/2/3/4/6/8/12/18/24/36/48/72/96/120/144/168 hours.</description>
          <units>none (ratio)</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bisnorbiotin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1731" lower_limit="0.082" upper_limit="0.267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Biotin sulfoxide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0204" lower_limit="0.014" upper_limit="0.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Whole Blood: Plasma Concentration Ratios of Total Radioactivity</title>
        <description>Total radioactivity in whole blood versus total radioactivity in plasma concentration ratios at time intervals following a single oral administration of 100mg [14C]-MD1003 Measured at 0/1/1.5/2/3/4/6/8/12/18/24/36/48/72/96/120/144/168 hours.</description>
        <time_frame>Pre-dose to 168 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MD1003</title>
            <description>radiolabeled 14C MD1003 (High Dose Biotin) 100mg&#xD;
[14C]-MD1003: single oral dose of 100mg [14C]-MD1003</description>
          </group>
        </group_list>
        <measure>
          <title>Whole Blood: Plasma Concentration Ratios of Total Radioactivity</title>
          <description>Total radioactivity in whole blood versus total radioactivity in plasma concentration ratios at time intervals following a single oral administration of 100mg [14C]-MD1003 Measured at 0/1/1.5/2/3/4/6/8/12/18/24/36/48/72/96/120/144/168 hours.</description>
          <units>% radioactivity whole blood/plasma</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 H</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.298" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 H</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.931" spread="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 H</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.365" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 H</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.708" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Adverse Events (AEs)</title>
        <description>2 months</description>
        <time_frame>Overall period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MD1003</title>
            <description>radiolabeled 14C MD1003 (High Dose Biotin) 100mg&#xD;
[14C]-MD1003: single oral dose of 100mg [14C]-MD1003</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Adverse Events (AEs)</title>
          <description>2 months</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Adverse Drug Reactions as Assessed by Investigator</title>
        <time_frame>Overall period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MD1003</title>
            <description>radiolabeled 14C MD1003 (High Dose Biotin) 100mg&#xD;
[14C]-MD1003: single oral dose of 100mg [14C]-MD1003</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Adverse Drug Reactions as Assessed by Investigator</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Systolic Blood Pressure in mmHg</title>
        <description>Change from baseline measure (defined as Day 1, pre-dose). Measured at screening/Pre-dose/1/4/24/72/168 hours.</description>
        <time_frame>Pre-dose to Day 10</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MD1003</title>
            <description>radiolabeled 14C MD1003 (High Dose Biotin) 100mg&#xD;
[14C]-MD1003: single oral dose of 100mg [14C]-MD1003</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Systolic Blood Pressure in mmHg</title>
          <description>Change from baseline measure (defined as Day 1, pre-dose). Measured at screening/Pre-dose/1/4/24/72/168 hours.</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1H</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4H</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24H</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72H</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Diastolic Blood Pressure in mmHg</title>
        <description>Change from baseline measure (defined as Day 1, pre-dose). Measured at screening/Pre-dose/1/4/24/72/168 hours.</description>
        <time_frame>Pre-dose to Day 10</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MD1003</title>
            <description>radiolabeled 14C MD1003 (High Dose Biotin) 100mg&#xD;
[14C]-MD1003: single oral dose of 100mg [14C]-MD1003</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Diastolic Blood Pressure in mmHg</title>
          <description>Change from baseline measure (defined as Day 1, pre-dose). Measured at screening/Pre-dose/1/4/24/72/168 hours.</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1H</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4H</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24H</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72H</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Heart Rate in Beats Per Minute</title>
        <description>Change from baseline measure (defined as Day 1, pre-dose). Measured at screening/Pre-dose/1/4/24/72/168 hours.</description>
        <time_frame>Pre-dose to Day 10</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MD1003</title>
            <description>radiolabeled 14C MD1003 (High Dose Biotin) 100mg&#xD;
[14C]-MD1003: single oral dose of 100mg [14C]-MD1003</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Heart Rate in Beats Per Minute</title>
          <description>Change from baseline measure (defined as Day 1, pre-dose). Measured at screening/Pre-dose/1/4/24/72/168 hours.</description>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1H</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.7" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4H</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.0" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24H</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72H</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in ECG (Electrocardiogram) QTcF Interval in Milliseconds</title>
        <description>Change from baseline measure (defined as Day 1, pre-dose). Measured at screening/Pre-dose/1/4/24/72/168 hours.</description>
        <time_frame>Pre-dose to Day 10</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MD1003</title>
            <description>radiolabeled 14C MD1003 (High Dose Biotin) 100mg&#xD;
[14C]-MD1003: single oral dose of 100mg [14C]-MD1003</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in ECG (Electrocardiogram) QTcF Interval in Milliseconds</title>
          <description>Change from baseline measure (defined as Day 1, pre-dose). Measured at screening/Pre-dose/1/4/24/72/168 hours.</description>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1H</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4H</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24H</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From Day -28 to Day 8</time_frame>
      <group_list>
        <group group_id="E1">
          <title>MD1003</title>
          <description>radiolabeled 14C MD1003 (High Dose Biotin) 100mg&#xD;
[14C]-MD1003: single oral dose of 100mg [14C]-MD1003</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA; v 22.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Frédéric SEDEL, Chief Scientific Officer and Co-founder</name_or_title>
      <organization>MedDay Pharmaceuticals</organization>
      <phone>+33 1 80 40 14 40</phone>
      <email>frederic.sedel@medday-pharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

